Skip to main content
Terug
Watch Compare

Avalo Therapeutics, Inc.

Datakwaliteit: 100%
AVTX
NASDAQ Manufacturing Chemicals
€ 13,66
▼ € 0,55 (-3,87%)
Marktkapitalisatie: 322,91 M
Prijs
€ 14,17
Marktkapitalisatie
322,91 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -67,67% annually over 5 years
Negative free cash flow of -51,46 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 18,95%

Groei

Revenue Growth (5Y)
-67,67%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)-86,62%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-79,81%
Onder sectorgemiddelde (-54,01%)
ROIC-49,15%
Net Margin-132642,37%
Op. Margin-123601,69%

Veiligheid

Debt / Equity
N/A
Current Ratio14,28
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-4,13 | -4,50
Onder sectorgemiddelde (-1,49)
P/B Ratio3,53
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -4,1 -1,5
P/B 3,5 1,6
ROE % -79,8 -54,0
Net Margin % -132642,4 -41,5
Rev Growth 5Y % -67,7 1,8
D/E — 0,3

Koersdoel Analisten

11 analisten
Buy
Huidig
€ 13,66
+193.5%
Koersdoel
€ 40,09
€ 24,00
€ 40,00
€ 52,00
Vooruitzicht
Forward K/W -4,50
Forward WPA -€ 3,03
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 3,03
-€ 3,98 – -€ 1,33
 0,0 6
FY2026 -€ 3,24
-€ 3,67 – -€ 2,41
 0,0 6

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 1,50 -€ 0,37 +75,3%
Q32025 -€ 1,64 -€ 2,19 -33,7%
Q22025 -€ 1,46 -€ 1,92 -31,7%
Q12025 -€ 1,61 -€ 1,25 +22,1%

ETFs Holding This Stock

AVDV logo AVDV Avantis International Small Cap Value ETF
0,00% weight
AVDS logo AVDS Avantis International Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -86,62% Revenue Growth (3Y) -82,49%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -67,67% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 59.000,0 Net Income (TTM) -78,26 M
ROE -79,81% ROA -62,19%
Gross Margin N/A Operating Margin -123601,69%
Net Margin -132642,37% Free Cash Flow (TTM) -51,46 M
ROIC -49,15% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 14,28
Interest Coverage N/A Asset Turnover 0,00
Working Capital 105,87 M Tangible Book Value 81,05 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,13 Forward P/E -4,50
P/B Ratio 3,53 P/S Ratio 5473,09
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15,94%
Market Cap 322,91 M Enterprise Value 295,95 M
Per Share
EPS (Diluted TTM) -5,84 Revenue / Share 0,00
FCF / Share -2,26 OCF / Share -2,26
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 65,75%
SBC-Adj. FCF -62,42 M Growth Momentum -18,95

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 59.000,0 441.000,0 1,92 M 18,05 M 5,40 M
Net Income -78,26 M -35,13 M -31,54 M -41,66 M -84,38 M
EPS (Diluted) -5,84 -20,91 -114,00 -4,43 —
Gross Profit — — — — —
Operating Income -72,93 M -68,51 M -27,35 M -37,44 M -82,13 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — 10,30 M — —
D&A 344.000,0 169.000,0 158.000,0 166.000,0 1,66 M
Interest Expense — — — — —
Income Tax 165.000,0 114.000,0 14.000,0 28.000,0 -196.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 116,46 M 150,73 M 20,99 M 33,37 M 80,21 M
Total Liabilities 33,41 M 17,70 M 13,69 M 44,28 M 57,13 M
Shareholders' Equity 83,05 M 133,03 M 7,30 M -10,92 M 23,08 M
Total Debt — — — — —
Cash & Equivalents 15,86 M 134,55 M 7,42 M 13,17 M 54,59 M
Current Assets 105,29 M 138,89 M 8,40 M 16,42 M 61,85 M
Current Liabilities 12,94 M 6,96 M 4,62 M 22,11 M 19,89 M